date:2019-01-02 Views:8687 times
查看研報附件:信達國際-康臣藥業(yè)1681:2018年上半年收入實現(xiàn)穩(wěn)定增長,推薦買入評級,目標價9.6港元。
Prev:China / Hong Kong Company Guide Consun Pharmaceutical Group
Next:None
400-930-1681
service@chinaconsun.com
71 Dongpeng Avenue, Huangpu District, Guangzhou
Friendship Link: State Food and Drug Administration Inner Mongolia Food and Drug Administration Guangdong Food and Drug Administration Guangxi Food and Drug Administration
粵ICP備15001491號Design: uweb